- Home
- VIGL vs IMPP Comparison
VIGL vs IMPP Comparison
Compare VIGL & IMPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- IMPP
- Stock Information
- Founded
- VIGL 2020
- IMPP 1981
- Country
- VIGL United States
- IMPP Greece
- Employees
- VIGL N/A
- IMPP N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- IMPP Marine Transportation
- Sector
- VIGL Health Care
- IMPP Consumer Discretionary
- Exchange
- VIGL Nasdaq
- IMPP Nasdaq
- Market Cap
- VIGL 141.5M
- IMPP 119.7M
- IPO Year
- VIGL 2022
- IMPP N/A
- Fundamental
- Price
- VIGL $3.00
- IMPP $3.40
- Analyst Decision
- VIGL Buy
- IMPP
- Analyst Count
- VIGL 5
- IMPP 0
- Target Price
- VIGL $16.80
- IMPP N/A
- AVG Volume (30 Days)
- VIGL 51.3K
- IMPP 160.9K
- Earning Date
- VIGL 11-07-2024
- IMPP 12-03-2024
- Dividend Yield
- VIGL N/A
- IMPP N/A
- EPS Growth
- VIGL N/A
- IMPP N/A
- EPS
- VIGL N/A
- IMPP 1.69
- Revenue
- VIGL N/A
- IMPP $147,505,660.00
- Revenue This Year
- VIGL N/A
- IMPP N/A
- Revenue Next Year
- VIGL N/A
- IMPP $36.53
- P/E Ratio
- VIGL N/A
- IMPP $2.02
- Revenue Growth
- VIGL N/A
- IMPP N/A
- 52 Week Low
- VIGL $2.47
- IMPP $1.57
- 52 Week High
- VIGL $6.06
- IMPP $4.59
- Technical
- Relative Strength Index (RSI)
- VIGL 32.87
- IMPP 26.40
- Support Level
- VIGL $2.89
- IMPP $3.29
- Resistance Level
- VIGL $3.26
- IMPP $3.56
- Average True Range (ATR)
- VIGL 0.22
- IMPP 0.10
- MACD
- VIGL -0.08
- IMPP -0.00
- Stochastic Oscillator
- VIGL 9.40
- IMPP 22.00
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.